Sun Pharma launches first branded ophthalmic product BromSite in US

Sun Pharma has launched its first branded ophthalmic product, BromSite (bromfenac ophthalmic solution) 0.075%, in the US market. A non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of post-operative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company’s branded ophthalmic business division.  
 

Approved by the US FDA on April 8, 2016, BromSite is the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery. Developed by California-based InSite Vision, a subsidiary of Sun Pharma, it is also the first bromfenac ophthalmic solution formulated in DuraSite, a polymer-based drug delivery system that is used to improve drug solubility, absorption, bioavailability, and residence time as compared to conventional topical therapies.

“As the first branded ophthalmic product launched by Sun Ophthalmics business division, BromSite’s launch is a significant milestone for Sun Pharma in the US. We are confident BromSite will prove itself a quality treatment option for cataract surgeons and their patients. Furthermore, with several promising candidates in our ophthalmics pipeline, Sun Ophthalmics is positioned to provide eye care professionals additional, quality treatment options in the near future,” commented Abhay Gandhi, CEO - North America Business, Sun Pharma.

Jerry St. Peter, vice president & head - Sun Ophthalmics, added, “This is an exciting, important moment for Sun Ophthalmics. The BromSite launch marks not only the unveiling of our first brand, but the entry of a new, robust sales force and marketing team dedicated to optimal customer service. We are committed to providing products that enhance doctors’ practice patterns and treatment options, as well as delivering these products through a talented, knowledgeable, and responsive commercial team. BromSite is our first opportunity to prove that commitment to eye care professionals.”